Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 11, 2002, Pages 1933-1938

  Murakami, K ^a   Sato, R ^a   Okimoto, T ^a   Nasu, M ^a   Fujioka, T ^a   Kodama, M ^a   Kagawa, J ^a   Sato, S ^b   Abe, H ^b   Arita, T ^b  

^a OITA UNIVERSITY   (Japan)

^b Arita Gastrointestinal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; URTICARIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; STOMACH ULCER;

EID: 18644362493     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01368.x     Document Type: Article

References (22)

1. Asaka M, Satoh K, Sugano K, et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001: 6: 177-86.
2. Murakami K, Fujioka T, Okimoto T, et al. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002: 19: 67-70.
3. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999: 12: 19-26.
4. Megraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: A review of current data. Gut 1998: 43(Suppl. 1): S61-5.
5. Vakil N, Hahn B, McSoley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998: 93: 1423-35.
6. Adamek RJ, Suerbaum S, Phaffenbach B, et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - Influence on treatment outcome. Am J Gastroenterol 1998: 93: 386-9.
7. Fujisaki H. Shibata H, Oketani K, et al, Effects of the proton pump inhibitor. E3810, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Drug Invest 1991: 3(5): 328-32.
8. Tomiyama Y, Morli M, Takeguti N, et al. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994: 48(11): 2049-55.
9. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - A European multicentre study. Aliment Pharmacol Ther 1998: 12: 789-95.
10. Williams MP, Sercombe J, Pounder RE, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998: 12: 1079-89.
11. Hirai M, Azuma T, Ito S, et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995: 30: 461-4.
12. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Tenth Information Supplement (Aerobic Dilution) M100-S10. National Committee for Clinical Laboratory Standards. PA. USA. 2000.
13. Furuta T, Ohashi K, Kaneko E, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998: 129: 1027-30.
14. Tanigawa Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999: 66: 528-34.
15. Furuta T, Shirai N, Ohashi K, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxycillin, and clarithromycin. Clin Pharmacol Ther 2001: 9: 158-68.
16. Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl 3): 27-36.
17. Adachi K, Katsube T, Kinosita Y, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000: 14: 1259-66.
18. Shirai N, Furuta T, Hanai H, et al. Effect of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001: 15: 1929-37.
19. Lind T, Zanten SV, Unge R, et al, Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH-1 study. Helicobacter 1996: 1: 138-44.
20. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on the triple therapy with lansoprazole/amoxycillin/clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001: 6(3): 254-61.
21. Kihira K, Satoh K, Sugano K, et al. Rabeprazole. amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000: 14: 1083-7.
22. Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection. Dig Dis Sci 2000: 45: 77-82.